CoChat

Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management

Taha, Mohamad B., Yahya, Tamer, Satish, Priyanka, Laird, Rachel, Agatston, Arthur S., Cainzos-Achirica, Miguel, Patel, Kershaw V., Nasir, Khurram · 2022 · Current Atherosclerosis Reports

The DOI matches its Crossref record; 78 of the 79 references it cites were found in a registry or an index.

Abstract

Purpose of review The burden of obesity worldwide is high and projected to rise. Obesity increases the risk of several cardiovascular diseases and cardiometabolic risk factors; hence, utilizing effective long-term therapies for obesity is of utmost importance. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective therapies that achieve substantial weight loss and improve cardiometabolic risk. The purpose of this review is to discuss the role of GLP-1RAs in obesity management. Recent findings Two subcutaneous GLP-1RAs, liraglutide and semaglutide, have been evaluated in several clinical trials for weight loss. Liraglutide achieves a mean weight loss of 4-7 kg, and more than 50% of treated individuals achieve 5% or more weight loss. Semaglutide has a greater impact on weight loss, with a mean weight loss of 9-16 kg, and more than 50% of treated individuals achieve 10-15% or more weight loss. These results led to regulatory approval of these agents for weight loss in individuals with obesity, regardless of diabetes status. In addition to weight loss, the benefits of GLP-1RAs extend to other risk factors, such as glycemic control and blood pressure. Gastrointestinal symptoms are the most frequently encountered adverse events with incidences between 5 and 30%. Finally, the cost remains one of the most critical challenges that limit GLP-1RAs use. GLP-1RAs have robust weight loss benefits and are expected to have a critical role in the management of obesity…

Overview

Integrity signals

Registry

Crossref · 10.1007/s11883-022-01041-7

Cites

78 of 79 references verified0 citation errors · 1 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 79 references

Research works printed but not linked: 2

  1. O’Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637–49. · DOI · Paper page
  2. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, Neil PMO, Rubino DM, Skovgaard D, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity the STEP 3 randomized clinical trial. JAMA. 2021;325:1403–13. · DOI · Paper page

Cited by

See all 31

Metadata

Authors
Taha, M. B., Yahya, T., Satish, P., Laird, R., Agatston, A. S., Cainzos-Achirica, M., Patel, K. V., & Nasir, K.
Affiliations
  • Houston Methodist (US)
  • Florida International University (US)
Corresponding author
Nasir, Khurram
Venue
Current Atherosclerosis Reports
Published
2022-05-28
Volume
24
Issue
8
Pages
643-654
ISSN
  • 1523-3804 (ISSN-L)
  • 1534-6242
OpenAlex
W4282033247
Cited by
31
References
76
Citations by year
2026: 4 · 2025: 8 · 2024: 10 · 2023: 4 · 2022: 5
FWCI
0.97
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Current Atherosclerosis Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
GLP-1 receptor agonists, obesity treatment, weight loss, liraglutide, semaglutide, cardiometabolic risk, glycemic control, blood pressure, gastrointestinal adverse effects, cost barriers, cardiovascular outcomes
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Obesity Management, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Weight Loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. https://app.cochat.ai/papers/10.1007/s11883-022-01041-7
The paper
Taha, M. B., Yahya, T., Satish, P., Laird, R., Agatston, A. S., Cainzos-Achirica, M., Patel, K. V., & Nasir, K. (2022). Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-022-01041-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.